Can a New Board Appointment Reverse CONMED’s Fortunes?
18.09.2025 - 07:27:03 | boerse-global.deThe medical technology firm CONMED has appointed a new director to its board, bringing in seasoned industry executive Kim Kelderman, the current Chief Executive Officer of Bio-Techne. This strategic addition comes at a critical juncture for the company, whose shares have declined by over a third since the start of the year and continue to trade under significant pressure.
Kelderman’s appointment is viewed as a substantive move rather than a routine board refresh. He brings extensive leadership experience from major industry players, including Thermo Fisher Scientific and Becton Dickinson. In a clear signal of the weight his role is expected to carry, he was also appointed to key positions on the board’s governance and strategy committees. This suggests a concerted effort by management to implement a... Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Für. Immer. Kostenlos.
